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Haploinsufﬁciency for ANKRD11-ﬂanking genes
makes the difference between KBG and 16q24.3
microdeletion syndromes: 12 new cases
Francesca Novara*,1,24, Berardo Rinaldi*,1,24, Sanjay M Sisodiya2,3, Antonietta Coppola4, Sabrina Giglio5,6,
Franco Stanzial7, Francesco Benedicenti7, Alan Donaldson8, Joris Andrieux9, Rachel Stapleton10, Astrid Weber11,
Paolo Reho1, Conny van Ravenswaaij-Arts12, Wilhelmina S Kerstjens-Frederikse13, Joris Robert Vermeesch14,
Koenraad Devriendt14, Carlos A Bacino15,16, Andrée Delahaye17,18,19, S M Maas20,21, Achille Iolascon22,23 and
Orsetta Zuffardi*,1
16q24 deletion involving the ANKRD11 gene, ranging from 137 kb to 2 Mb, have been associated with a microdeletion syndrome
characterized by variable cognitive impairment, autism spectrum disorder, facial dysmorphisms with dental anomalies, brain
abnormalities essentially affecting the corpus callosum and short stature. On the other hand, patients carrying either deletions
encompassing solely ANKRD11 or its loss-of-function variants were reported in association with the KBG syndrome, characterized
by a very similar phenotype, including mild-to-moderate intellectual disability, short stature and macrodontia of upper incisors, with
inter and intrafamilial variability. To assess whether the haploinsufﬁciency of ANKRD11-ﬂanking genes, such as ZFPM1, CDH15
and ZNF778, contributed to either the severity of the neurological impairment or was associated with other clinical features, we
collected 12 new cases with a 16q24.2q24.3 deletion (de novo in 11 cases), ranging from 343 kb to 2.3 Mb. In 11 of them, the
deletion involved the ANKRD11 gene, whereas in 1 case only ﬂanking genes upstream to it were deleted. By comparing the clinical
and genetic features of our patients with those previously reported, we show that the severity of the neurological phenotype and the
frequency of congenital heart defects characterize the deletions that, besides ANKRD11, contain ZFPM1, CDH15 and ZNF778 as
well. Moreover, the presence of thrombocytopenia and astigmatism should be taken into account to distinguish between 16q24
microdeletion syndrome and KBG syndrome. The single patient not deleted for ANKRD11, whose phenotype is characterized by
milder psychomotor delay, cardiac congenital malformation, thrombocytopenia and astigmatism, conﬁrms all this data.
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INTRODUCTION
KBG syndrome is one of many rare diseases associated with
intellectual disability but with otherwise nonspeciﬁc clinical handles.
The presence of macrodontia of the permanent maxillary incisors
remains the most evocative clinical sign. Other common features
suggested as major criteria for the clinical diagnosis are: characteristic
facial dysmorphisms, hand anomalies, neurological involvement,
delayed bone age, costovertebral anomalies, postnatal short stature
and the presence of a ﬁrst-degree relative with KBG.1
Heterozygous loss-of-function (LoF) variants in the ANKRD11 gene
at 16q24.3 have been identiﬁed to be causative for KBG syndrome.2,3
Mild-to-moderate intellectual disability is a KBG feature but
individuals with only minor learning difﬁculties have been reported,
so that not only de novo but also inherited or familial cases have
been observed.3 Vertical transmission has been related to low-
grade mosaicism as well, responsible for a milder phenotypic
presentation.4,5 Beside single-nucleotide variants,2,3,6–10 KBG syndrome
has been associated with 16q24.3 microdeletions or intragenic
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microduplications encompassing only the ANKRD11 gene and thus
resulting in its haploinsufﬁciency (Supplementary Table S1).4,5,11–14
On the other hand, at least eight cases of 16q24.3 microdeletions
involving other genes besides ANKRD11 have been reported so far
(Supplementary Table S1),3,15,16,17 and, among the ﬂanking genes,
ZNF778, CDH15, ZFPM1 and SPG7 have been pointed out for a
possible role in the resulting phenotype.16 By comparing clinical
features of patients with ANKRD11 LoF variants versus those with
16q24.3 microdeletions, Ockeloen et al3 concluded that the frequency
of congenital anomalies, seizures and behavioral problems appeared to
be similar in both groups. However, owing to the low number of
patients, the authors could not exclude that the severity of neurological
symptoms and intellectual disability was greater in cases where the
deletion included other genes, besides ANKRD11.
We report on 12 new individuals with deletions of 16q24.2q24.3,
originated de novo in 11 patients and of unknown origin in the
remaining one. We compare the clinical and genetic features of our
patients with those previously reported, in order to clarify whether
haploinsufﬁciency of ANKRD11-ﬂanking genes contributed to either
the severity of the phenotype or the presence of distinctive clinical
features.
PATIENTS
Written informed consent was obtained from patients’ parents or
patients themselves. Only some have given consent for picture
publication. The relevant institutional ethics committees approved
this study. All patient data have been submitted to ClinVar (https://
www.ncbi.nlm.nih.gov/clinvar/).
Patient 1 (ClinVar SCV000328241)
He is the second child of unrelated and healthy parents, born at 41
+3 week of gestation (WG) with normal auxological parameters. At
birth a ventricular septal defect (VSD) and left cryptorchidism were
observed. Psychomotor development was slightly delayed and from
the infancy he presented moderate–severe astigmatism as well. At the
age of 5 years, short stature was evident. When he was 6 years and
11 months old, a psychometric evaluation evidenced a borderline
intellectual disability with overall IQ of 72 and main difﬁculties in
language and motor skills. Learning disabilities and attention deﬁcit-
hyperactivity disorder were also diagnosed. At 11 years and 9 months,
his stature was 128 cm (o − 2 SD). At the age of 12 years and
3 months, X-ray revealed bone age delay and bilateral prominent C7
transverse processes. Facial dysmorphisms included: prominent fore-
head, thin hair in the temporal regions, synophrys with sparse
eyebrows, prominent and posteriorly rotated ears, high nasal bridge
and nose with large root, anteverted nostrils with thickened alae of the
wings. Face was slightly asymmetric with mild retrogenia (Figures 1a
and b). Mouth was maintained preferentially open, with trapezoidal
morphology, full lips and downturned corners of the mouth.
Macrodontia of upper central incisors was evident. Moderate brachy-
dactyly was noted together with severe clinodactyly and shortness of
ﬁfth ﬁngers, proximally placed thumbs and ﬂat feet. Platelets count
was normal.
Patient 2 (DECIPHER patient SMB255327, ClinVar SCV000328242)
He was born at 38 WG following a normal pregnancy. Birth weight
was ~ 2 kg (o− 2 SD) and he experencied feeding problems for the
ﬁrst 6 months. Neonatal investigations revealed a VSD. Motor
milestones were delayed, and hypotonia was present from the age of
1 year. He had a diagnosis of cerebral palsy. An abnormality of his
primary dentition, not otherwise deﬁned, was noted but adult teeth
were normal. At the age of 22 years old, verbal IQ was 67 and
performance IQ of 62. On the examination at the age of 26 years old,
occipito-frontal circumference (OFC) was 4+1 SD, weight was
Figure 1 Facial pictures of four new patients: patient 1 at 8 and 11 years of age (a, b), patient 5 at 6 years of age (c), patient 11 at 7 and 14 years of age
(d, e), patient 12 at 13 years of age (f).
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normal, heighto− 1 SD and body mass index (BMI) was 29.8 kg/m2
(overweight). He had a round face with deep set eyes, prominent
forehead, short ﬁngers and small feet. The patient has had several full
blood analysis, including platelets counts and volume, which resulted
to be always within the normal range.
Patient 3 (DECIPHER patient JFL255929, ClinVar SCV000328243)
He was the third child of young and unrelated parents, born at 38 WG
with normal biometric values after a pregnancy complicated of
polyhydramnios and minor cerebral ventriculomegaly. Cardiac and
abdominal defects were excluded. He was referred for minor cognitive
impairment with speech defect. He walked alone at 18 months. At 8
years and 9 months his height was − 1 SD, the weight o− 2 SD and
OFC 4+2 SD. He presented with macrodontia with teeth malposi-
tion, myopia and astigmatism, long palpebral ﬁssures and pointed chin
and a premature puberty (stage I according to Tanner scale). He had
ﬁngers pads and complex inner and middle ear abnormalities
associated with conductive hearing deafness, improved by tympano-
plasty. Platelets count was normal.
Patient 4 (DECIPHER patient WLN265435, ClinVar
SCV000328244)
He is the ﬁrst child of unrelated parents, born from a intracytoplasmic
sperm injection pregnancy because of polycystic ovarian disease and
low sperm count. Pregnancy was complicated by intrauterin growth
restriction (IUGR) and polyhydramnios. Delivery was induced at 38
WG and all body measurements were around or below − 2 SD. He
presented with developmental delay (especially expressive language
delay), good receptive language and social ability, delayed achievement
of motor milestones. He showed short stature, consistently below − 2
SD, with normal OFC and delayed bone age. Ears were low set and
posteriorly rotated. Among his facial dysmorphisms: broad nose with a
bulbous tip, low nasal bridge and smooth philtrum, high and
prominent forehead, frontal bossing, arched eyebrows, low nasal
bridge and pointed chin were present. Single palmar crease right
hand, proximally placed thumbs, rounded distal phalanx of thumbs
and big toes were noted. The cardiac ultrasound (US) evaluation
identiﬁed a small muscular and one membranous VSD with mildly
dysplastic pulmonary valve. The computed tomography (CT) scan
brain was normal. The patient has always had normal platelet counts
and volume, at least until the age of 3 years and 2 months.
Patient 5 (DECIPHER patient MCG251801, ClinVar
SCV000328245)
This boy was born at term from uncomplicated pregnancy. In the ﬁrst
months of life, he developed gastro-esophageal reﬂux causing failure to
thrive, which resolved by 2 years of age. He smiled at 8–9 weeks, sat
independently at 8–9 months and walked independently at 18 months
of age. He spoke his ﬁrst recognizable words at 2 years 3 months of
age. He came to medical attention at 2 years of age because of gastro-
esophageal reﬂux, macrocephaly with mild plagiocephaly, develop-
mental delay, right cryptorchidism, mild muscular hypotonia and
some dysmorphic features (prominent forehead, round face, arched
eyebrows, large and low set ears and broad nose, see Figure 1c). He
suffered from recurrent blepharitis and bilateral sensorineural hearing
loss. Blood tests were all normal.
Patient 6 (ClinVar SCV000328246)
This is the only patient for whom ANKRD11 is not deleted (see
Figure 2).
The boy was born by emergency cesarean section because of fetal
distress after 37 WG. He suffered from perinatal asphyxia, cardiovas-
cular and respiratory insufﬁciency, pulmonary hypertension and
transient thrombocytopenia (platelets count – day 1: 29× 109/l, day
9: 18× 109/l; day 20: 51× 109/l, day 29: 128× 109/l, day 56: 329× 109/l
and normal afterward). Bilateral adrenal hemorrhages resulted in
adrenal insufﬁciency. A small muscular VSD and congenital hypothyr-
oidism were detected. Magnetic resonance (MR) at age 1 year showed
post asphyxia damage, in absence of cerebral structural anomalies. He
wears glasses because of severe astigmatism. At the age of 6 years, he
attends a regular school but needed extra support and had a short
attention span. He showed mild dysmorphic features: a high forehead
Figure 2 Correlation between the size of the microdeletions and the clinical features in the reported cases (11 sporadic and 2 familial, light red) and the 12
novel ones (dark red). The case with intragenic micoduplication is also reported in green. Genes in blue are those we considered mainly responsible for the
clinical features in 16q24.3 microdeletions. Case 6 is the only one whose deletion does not include the ANKRD11 gene.
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with frontal bossing, a deep nasal bridge and asymmetrically
placed ears.
Patient 7 (ClinVar SCV000328247)
The boy was born after an uneventful pregnancy and delivery.
A diagnosis of pervasive developmental disorder not otherwise
speciﬁed associated with developmental coordination disorder was
made. His performal IQ was 67, his verbal IQ was 81. He presented
with short stature (156.7 cm, − 1 SD) and normal weight, OFC and
BMI. He had mild facial dysmorphisms: round face with high and
broad forehead, large incisors and a preauricular tag at the right side.
He had proximally implanted thumbs. He wore glasses for astigma-
tism. He showed apraxia and a stiffened gait with retraction of Achilles
tendons. Blood tests did not reveal any abnormal values. The boy
followed special education till the age of 12, afterward he was able to
switch to regular low-level education.
Patient 8 (ClinVar SCV000328248)
This 29 year old man is the only child of unrelated parents. He was
born at term by an emergency cesarean section because of breech
presentation. His developmental milestones were slightly delayed: he
smiled at 2 months, sat up at 9 months and walked unaided at
17 months. His speech was severely impaired as he started speaking at
the age of 4. This problem was worsened by severe secretory otitis
media, which required tympanostomy and grommets. At the age of 3,
he underwent orchidopexy for undescended testes. At the age of 5, he
was diagnosed with autism and attended a special needs schools. He
suffered from epilepsy from the age of 15 years; at the onset seizures
were generalized tonic–clonic with perioral cyanosis. Electroencepha-
lography (EEG) showed left temporal abnormalities. From that time,
he experienced about three to four episodes per year, sometimes
occurring in clusters, despite antiepileptic therapy. Seizures disap-
peared by the age of 23 years. At the time of the ﬁrst evaluation (25
years old), his physical examination showed clear dysmorphisms:
forehead cleft with collapsed nasal bridge, bilateral ptosis (worse on
the left), and a high, arched palate. He also presented with levoconvex
scoliosis. Neurological examination showed anosmia, slow and hypo-
metric saccades, impaired upgaze with frontalis overactivity, right
exotropia and failure of convergence. He was markedly hypometric on
ﬁnger–nose testing. His tendon reﬂexes were subdued. He also had a
history of anxiety, angry outbursts and impulsivity. At the age of 20,
his full scale IQ score was 74 (borderline intellectual functioning).
Blood tests revealed a subclinical low platelet count (138× 109/l), low
serum urea and creatinine. Cardiac and renal ultrasound examinations
were normal. Video-telemetry EEG showed abnormal interictal
activity with widespread slowing, on some occasions more evident
over the right hemisphere. Frequent epileptiform abnormalities were
present over the left temporal region and were rarely also seen on the
right side. Cerebral MR showed a mega cisterna magna and biparietal
parenchymal loss; the body of the left hippocampus demonstrated a
slightly atypical morphology without a deﬁnite malformation or signal
abnormality.
Patient 9 (ClinVar SCV000328249)
This is the third child of healthy, unrelated parents. He was born at a
gestational age of 38 WG by C-section because of IUGR, VSD and fetal
distress. At birth, all his measurements were below − 2 SD. At the age
of 1 month, low platelets count was observed (40× 109/l). Clinical
examination at age of 3 years and 3 months revealed: weight 10.7 kg
(o − 2 SD), height 85.3 cm (o − 2 SD ) and OFC 49.7 cm (normal).
His psychomotor development was mildly delayed. He had mild
bilateral eyelid ptosis and one café-au-lait spot on the left leg. His
cerebral MR imaging revealed a delayed myelination.
Patient 10 (ClinVar SCV000328250)
She was referred at 7 months and then at 22 months for the
association between global developmental delay and congenital heart
defects (CHDs). OFC was below − 2 SD both at 7 months (39.9 cm)
and at 22 months (42.8 cm). She did not showed any dysmorphic
facial features. Cardiac US assessment identiﬁed: hypoplasia of left
ventricle, aortic annulus, aortic arch, cleft mitral valve with a
combination of mitral stenosis and insufﬁciency. Pulmonary hyper-
tension was resolved after mitral valve surgery at 9 months. Normal
platelets count was observed. She manifested a possible seizure episode
at 4 years of age, consisting in tonic extension with ﬁxed gaze followed
by lethargy. The EEG showed a diffuse, very slow background activity,
slow occipital rhythm, lateralization to the left occipital-posterior lobe
temporal activity. A CT scan of the brain at 4 years of age showed a
possible underdevelopment of the inferior cerebellar vermis. At the
same age, her general condition worsened, the patient went into shock
and died some months after.
Patient 11 (DECIPHER patient PAR259954, ClinVar
SCV000328251)
She is the ﬁfth child of healthy parents. Parents are ﬁrst-degree cousins
and all sisters and brothers are healthy. The pregnancy and the
delivery were uneventful. She had motor skill delay (sitting alone at 2
and a half years; walking alone at 4 years and 6 months). She had
absent language and autistic symptoms: poor eye contact and
interactions with others, stereotypies with hand ﬂapping and bruxism,
self-injurious behavior and sleep difﬁculties. She presented with facial
features characterized by macrodontia, synophris, hypertelorism, large
bulbous nose with anteverted nares and small extremities (Figures 1d
and e). Blood tests showed normal values of platelets count. She had
chronic rhinitis. She had drug-resistant generalized seizures since 1
year of age, and cerebral MR revealed bilateral atrophy of the cerebral
white matter.
Patient 12 (ClinVar SCV000328252)
The patient was born at 40 WG after an uncomplicated pregnancy;
family history was unremarkable. Her motor development was normal
but cognitive development was slow. She was evaluated at the age of
32 years because of psychiatric problems, showing an IQ of 65. At the
age of 45 years, she underwent surgical correction of hip dysplasia,
responsible of coxarthrosis. At the age of 48 years, she was re-evaluated
at the department of clinical genetics because of intellectual disability
and automutilation problems. She showed different skin lesions, such
as alopecia areata on the head, psoriasis of the extremities and at least
one episode of erysipelas in the previous years. She wore hearing aids
and glasses because of the severe myopia. Recently she had had an
operation of her left eye because of a mild facialis paresis.
At that time her height was 163.5 cm (−1 SD), weight 65 kg (+1 SD)
and OFC 56 cm (+1 SD). She was remarkably shy and her face was
round with a low frontal hair line, broad nose at the basis, long
smooth philtrum, cupid shape of the mouth with downturned corners
of the mouth (Figure 1f), and cutaneous syndactyly of toes II and III
and of ﬁngers II/III, III/IV and IV/V. Investigations (blood tests, EEG,
CT scan skull) were all normal.
METHODS
Array-CGH was performed with different platforms (see Supplementary Table S2).
Only in one case BAC array was used; in the latter case no further studies
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have been done. All data are reported according to February 2009 assembly,
GRCh37/hg19. Data conﬁrmation were performed by Q-PCR or FISH analysis
(Supplementary Table S2) with speciﬁc primers or probes (data not shown) and
extended to parents.
RESULTS
Molecular and clinical results
Supplementary Tables S1 and S2 recapitulate the deletion size and the
clinical features of the subjects with 16q24 microdeletions already
reported and of the 12 patients presented in this report, respectively.
A graphical overview of the same subjects is provided in Figure 2; the
deletion size for case 10 is unclear because an old BAC array showed a
single clone deletion for probe RP11-104N10 and no further studies
could be done (see * in Figure 2). The 16q24.2q24.3 deletions were
de novo in all the 11 cases we could analyze.
A comprehensive overview of main clinical features of patients with
either ANKRD11 variants, ANKRD11 deletion/duplication or 16q24.3
microdeletion is presented in Table 1, clearly showing that only
individuals with 16q24 microdeletion syndrome may manifest astig-
matism or thrombocytopenia. Although the small number of cases
prevent statistical signiﬁcance, both the frequency of CHDs and CNS
malformation show an higher incidence in patients with 16q24
microdeletion syndrome with respect to those with KBG syndrome.
DISCUSSION
Since 2011, KBG syndrome has been attributed to ANKRD11
haploinsufﬁciency.2 This gene encodes an ankryin repeat domain-
containing protein, which acts as a transcriptional coregulator and has
been shown to be crucial for neural development.18 To the best of our
knowledge, 23 ANKRD11 variants leading to KBG syndrome have
been described2,3,6,7,10 and other 2 ANKRD11 variants were reported
in patients with a more complex genotype.8,9 Most of these variants
are private, except for NM001256182.1c.1903_1907del highlighted in
three unrelated families,3,6 and are predicted to result in LoF of the
protein. Many ANKRD11 variants generate premature stop codons,
leading to the formation of a truncated protein. Recent insights about
the possible pathological mechanism underlying KBG syndrome have
shown that such truncated protein would accumulate inside the cell,
by escaping both mRNA decay process and proteasome-mediated
degradation.6 As ANKRD11 produces homodimers through N-termi-
nus interactions, the accumulation of the aberrant form of the protein
may suggest a dominant-negative mechanism, as already proved in the
murine model for KBG syndrome.6
Recently, a familial intragenic duplication of ANKRD11, predicted
to result in a truncated protein, has been associated with KBG
syndrome, reinforcing the evidence of a dominant-negative
mechanism.5 Besides intragenic variants, KBG syndrome can also be
caused by microdeletions encompassing part or the entire ANKRD11
gene. Up to now six individuals with such a deletion have been
identiﬁed.4,11–14 Three of these deletions include the SPG7 gene as
well,4,13,14 situated distally to ANKRD11; homozygous SPG7 variants
are associated with spastic paraplegia 7 (MIM #607259). Although a
possibly dominant effect has been suggested recently for some single
heterozygous variants, reports that deletions of this gene are patho-
genic only when homozygously present, make it unlikely that there is
any effect of SPG7 haploinsufﬁciency on the phenotypes of the cases
reported here.19
A phenotype overlapping the KBG syndrome has been described for
16q24.3 microdeletions. After the ﬁrst report of four cases by
Willemsen et al,16 other four patients have been reported involving,
at least in part, the ANKRD11 gene and extending more proximally up
to 2 Mb, encompassing among others, the ZFPM1, CDH15 and
ZNF778 genes.3,15,17 Recently, it has been questioned whether
haploinsufﬁciency for ﬂanking genes may contribute to a more
complex or a more severe phenotype.3
From the detailed genotype–phenotype investigation of our cohort
of 12 new cases with 16q24.3 microdeletions, we propose a tentative
correlation between some of the deleted genes and few speciﬁc traits,
identifying those distinctive clinical features possibly distinguishing
16q24.3 deletion from KBG syndrome.
Thrombocytopenia
The ZFPM1 (FOG1) gene, mapping about 730 kb upstream to
ANKRD11, is deleted in our patients 2, 3, 5, 6, 7 and 9 (Figure 2).
Table 1 Summary of the main clinical features in unrelated subjects with either isolated ANKRD11 alterations or 16q24.3 microdeletiona
Clinical featuresb ANKRD11 mutationc ANKRD11 deletiond ANKRD11 intragenic duplication 16q24.3 Microdeletion syndrome
Previous report This reporte Total
Gender 22 M
10 F
5 M
1 F
1 M
1 F
7 M
1 F
7 M
3 F
14 M
4 F
Characteristic facial anomalies 32/32 (100) 6/6 (100) 2/2 (100) 5/8 (62.5) 3/10 (30) 8/18 (44.4)
Macrodontia of upper central incisors 29/32 (90.6) 3/6 (50) 2/2 (100) 4/8 (50) 5/10 (50) 9/18 (50)
Postnatal short stature with height o3rd centile 20/32 (62.5) 5/6 (83.3) 2/2 (100) 2/8 (25) 4/10 (40) 6/18 (33.3)
Mild-to-moderate developmental delay 11/32 (34.4) 5/6 (83.3) 0/2 (0) 7/8 (87.5) 8/10 (80) 15/18 (83.3)
Mild-to-moderate intellectual disability 26/32 (81.3) 1/6 (16.7) 2/2 (100) 3/8 (37.5) 7/10 (70) 10/18 (55.6)
Seizures 7/32 (22) 1/6 (16.7) 0/2 (0) 3/8 (37.5) 2/10 (20) 5/18 (27.8)
CNSf malformation 1/32 (3.1) 0/6 (0) 0/2 (0) 3/8 (37.5) 2/10 (20) 5/18 (27.8)
Hand anomalies 29/32 (90.6) 4/6 (66.7) 2/2 (100) 3/8 (37.5) 2/10 (20) 5/18 (27.8)
Costovertebral anomalies 17/32 (53.1) 0/6 (0) 0/2 (0) 0/8 (37.5) 0/10 (0) 0/18 (0)
Signiﬁcantly delayed bone age 10/32 (31.3) 2/6 (33.3) 0/2 (0) 2/8 (25) 3/10 (30) 5/18 (27.8)
Cryptorchidism 11/22 (50) 0/5 (0) 0/1 (0) 2/7 (28.6) 3/7 (42.9) 5/14 (35.7)
Thrombocytopenia 0/32 (0) 0/6 (0) 0/2 (0) 2/8 (25) 2/10 (20) 4/18 (22.2)
Severe astigmatism 0/32 (0) 0/6 (0) 0/2 (0) 2/8 (25) 3/10 (30) 5/18 (27.8)
CHDsg 3/32 (9.4) 0/6 (0) 2/2 (100) 2/8 (25) 4/10 (40) 6/18 (33.3)
First-degree relative with KBG 11/32 (34.4) 1/6 (16.7) 2/2 (100) 2/8 (25) 0/11 (0) 2/18 (11.1)
Bold values indicates the clinical features that distinguish 16q24.3 microdeletion syndrome from KBG syndrome.
aPatient 6 was excluded because ANKRD11 is not involved in the deletion region; patient 10 was excluded as well, being deletion was distal to ANKRD11.
bAccording to Skjei et al, revisited.
cReferences: 2,3,6,7,10.
dReferences: 4,11–14.
eOnly six out of seven patients were considered as one presented the deletion in mosaic.
fCentral nervous system.
gCongenital heart defects.
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This gene encodes a nine-zinc-ﬁnger transcriptional regulator required
for a proper differentiation and maturation of both megakaryocytes
and erythroid precursors,20 acting in concert with the hematopoietic
master regulator GATA1.21 The murine model knockout either for
ZFPM1 or GATA1 shows a similar lethal phenotype, consisting of
thrombocytopenia and severe anemia.22 Not surprisingly, three of the
deleted patients (our cases 6 and 9, and patient 3 in Willemsen et al)16
and the two with a breakpoint downstream ZFPM1 (our case 8 and
patient 2 in Willemsen et al)16 at 29 and 670 kb, respectively, present
with subclinical thrombocytopenia. For these latter two patients, a
position effect, altering ZFPM1 expression, appears very likely.
Accordingly, the region downstream ZFPM1 gene results to be quite
conserved in mammals (Supplementary Figure S1) and contains
ZFPM1:miR-106/302, a conserved mammalian microRNA regulatory
target site. Unfortunately, having gathered the cases from different
medical centers, biological samples to assess this point through speciﬁc
expression studies were not available.
Although most of the ZFPM1 deleted patients did not show
bleeding disorders, the role of ZFPM1 in hematopoiesis is reinforced
by the demonstration that knockout mice are severely affected by
thrombocytopenia.23 On the other hand, many variants in genes
related to thrombocytopenia show variable expression.24 Moreover,
ZFPM1 and GATA1 interact both functionally25 and physically,26 and
disruption of the normal interaction of ZFPM1 and GATA1 has been
linked to a range of inherited blood disorders.27
It is interesting that a paralog of ANKRD11, namely ANKRD26, is
linked to thrombocytopenia inherited in a dominant manner and that
ANKDR11 itself is expressed in bone marrow at high level. However,
the ﬁnding that none of the 38 KBG subjects, either mutated or
deleted for ANKDR11, showed thrombocytopenia makes unlikely its
involvement in this disorder (Table 1).
Astigmatism
ZFPM1 (FOG1) is also crucial for a correct eye development through
the interaction with other GATA factors and its haploinsufﬁciency
seems to be associated with severe astigmatism, as reported in our
cases 1, 3, 6 and 7, and patients 3 and 4 in Willemsen et al16
(Supplementary Tables S1 and S2, Figure 2). In particular, GATA3
seems to be strongly involved in correct lens development in the
murine model, with a speciﬁc expression in lens ﬁbers. Moreover,
Gata3 inactivation leads to a reduced differentiation and abnormal
apoptosis of the posterior lens ﬁber cells.28 On the other hand,
overexpression of the ﬂy homolog for FOG genes, Ush, results in
aberrant eye differentiation, probably by inhibition of the ﬂy homolog for
GATA4, Pnr.29 These two lines of evidences suggest a dosage-sensitive
mechanism underlying FOG-GATA-dependent eye development. In this
sense, the presence of severe astigmatism in patients 3 and 4 in Willemsen
et al16 and in our cases 3 and 6 may be explained by an impairment of
ZFPM1 function. Similarly, the lens defect found in our patient 1, whose
deletion breakpoint falls at 41 kb downstream to the 3′ of ZFPM1, may be
explained in term of disruption of regulatory elements of the gene, as
already hypothesized above for thrombocytopenia.
Congenital heart defects
FOG/GATA interaction has been demonstrated to be essential also for
heart embryogenesis. In zebraﬁsh, ZFPM1 mutants show aberrant
cardiac looping and pericardial edema secondary to hypoplastic
ventricular wall looping.30 In Drosophila, Ush overexpression causes
inhibition of cardiac cell proliferation, producing gaps in the heart
tube.29 Murine model knockouts for Gata4 die at 9.5 days post coitum
because of cardiac malformations.31 In humans, GATA4 and GATA6
(OMIM *600576 and *601656) haploinsufﬁciency are known to be
associated with CHDs, and in particular with VSDs. Taken together,
all of these reports suggest a possible role of ZFPM1 deletion in
causing CHDs. In fact, we report a higher incidence of CHDs for
16q24.3 microdeletion patients (patient 3 in Willemsen et al,16 and our
cases 1, 2, 4, 6 and 9, about total 40% of cases) in comparison with
KBG subjects (10%).
As discussed, ZFPM1 haploinsufﬁciency causes severe perturbations
during developmental stages, affecting in particular the hematopoietic
system, the eye and the heart. Crawford et al32 demonstrated that in
mice Pbp null mutations, coding for the peroxisome proliferator
activator receptor-binding protein, produce very similar defects in
embryogenesis, consisting of ventricular myocardium disruption, eye
aberrations and impaired hematopoiesis. The authors demonstrated
that PBP interacts with all GATA factors and that the lethal murine
phenotype is due to the dysfunction of factors within the GATA
family. The evidence of a common and reproducible phenotype
caused by a functional impairment in GATA elements, because of
the haploinsufﬁciency of one of their interactors, gives further support
to the possible contribution of ZFPM1 in the genesis of the 16q24.3
microdeletion phenotype.
Another gene deleted in 16q24.3 microdeleted patients with CHDs
is ZNF778, which belongs to the zinc-ﬁnger protein family and is
widely expressed both in the brain and in the heart. For its function of
transcriptional regulator, it is predicted to interact with GATA4 that,
as discussed above, has been demonstrated to be fundamental in heart
development (Supplementary Figure S2). In this sense, haploinsufﬁ-
ciency for ZNF778 may also contribute to the higher frequency of
CHDs, essentially VSDs, present in the 16q24 microdeletion syndrome
compared with KBG syndrome. For example, Sacharow et al15
described a patient with a VSD and supravalvular pulmonary stenosis,
for whom a deletion involving only ANKRD11 and ZNF778 was
identiﬁed. On the other hand, four out of six of our cases presenting
with CHDs are deleted for ZNF778 (cases 1, 2, 4 and 9).
The neurological phenotype
Patients with KBG syndrome because of a LoF variants in ANKRD11
gene may show: mild-to-moderate intellectual disability, epilepsy or
EEG anomalies, brain malformations, behavioral and autistic spectrum
disorders. On the contrary, KBG patients because of encompassing
only ANKRD11 have been reported, on average, to show milder
neurological involvement with developmental delay mostly limited to
language impairment, with borderline cognitive skills, lower frequen-
cies of epilepsy, autism spectrum disorders and CNS structural
aberrations (not all underwent neuroimaging studies). The milder
phenotype in patients with ANKRD11 haploinsufﬁciency compared
with those with an intragenic variant may be explained by the
dominant-negative effect of the latter as suggested by Walz et al.6
The putative role of the CDH15 gene for the neurological burden is
particularly relevant in term of structural brain abnormalities, as all
ﬁve patients presenting with such cerebral ﬁndings carry a 16q24.3
microdeletion including the CDH15 gene (Figure 2 and Table 1). The
CDH15 gene encodes cadherin 15, a calcium-dependent cell adhesion
molecule belonging to the cadherin family. Cadherins are expressed in the
entire human brain and their dysregulation so far has been associated
with many neuropsychiatric disorders, including intellectual disability,
schizophrenia and epilepsy.33 Regarding speciﬁcally CDH15, Bhalla et al34
identiﬁed four heterozygous non-synonymous variants in unrelated
female patients with mild-to severe intellectual disability. Functional
studies demonstrated reduced cell adhesion in murine cells expressing
mutated CDH15. However, in one case the variant had been inherited
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from a healthy parent, suggesting incomplete penetrance. The observation
of a worse neurological phenotype for larger deletions suggests a possible
role for CDH15 in regulating proper CNS embryogenesis.
Remarkably, some patients with a CDH15 deletion share speciﬁc clinical
traits with CHARGE syndrome, associated with heterozygous CDH7
variants. In particular, cases 8, 9 and the case described by Miyatake et al17
presented with ptosis, whereas case 8 presented anosmia as well.
Teeth anomalies
Impaired dental development is considered as the most speciﬁc clinical
sign for KBG syndrome and thus it has been listed among the major
diagnostic criteria. Different anomalies have been identiﬁed: macro-
dontia of the permanent upper central incisors (as deﬁned by
Moyers35), hypodontia, supernumerary mammelons, cleft teeth and
enamel hypoplasia or pits1 have all been documented. Such alterations
have been reported for almost all individuals with KBG syndrome
independently of the underlying molecular defect, namely ANKRD11
variant or deletion, although for two patients with an ANKRD11
deletion no permanent teeth anomalies were reported.12
The dental dysmorphisms reported in patients with 16q24.3
microdeletion are very similar to those described for ANKRD11
haploinsufﬁciency, albeit occurring with a lower frequency
(Table 1). It appears difﬁcult to gather all this data in a comprehensive
genotype–phenotype framework and such variability may be due to
the effect of other modiﬁer genes in the microdeletion.
Miscellaneous
Patient 9 carries the most proximal deletion of our cohort and his
phenotype is characterized also by renal malformation. Handrigan
et al36 reported an augmented incidence of renal malformations in
patients with deletion of the region 16q24.1q24.2. The area of minimal
overlap includes the genes FBXO31, MAP1LC3B and ZCCHC14 and
the deletion of our patient 9 extends to the distal end of the ZCCHC14
gene. It is then arguable that his kidney defect may be related to the
involvement of this region, possibly critical for renal development.
Crippa et al5 described two related KBG patients with an intragenic
ANKRD11 duplication. One of them had third-degree vesicoureteral
reﬂux and the other had left ureterocele and duplex pelvicalyceal
district. Renal abnormalities were not previously reported for the
exclusive involvement for ANKRD11, but the authors could not
exclude a random association.
In our cohort, patient 6 shows a proximal deletion not involving the
ANKRD11 gene and including only ZFPM1. His phenotype includes:
perinatal asphyxia, normal cognitive level, speech delay, no structural
anomalies in brain development, normal height and OFC, absent facial
dysmorphisms, neonatal transient thrombocytopenia, VSD and severe
astigmatism. This clinical presentation is quite different from those
because of larger deletions and supports the role of CDH15, ZNF778
and ANKRD11 in the 16q24.2 microdeletion syndrome and the
importance of ZFPM1 for cardiac, hematopoietic and eye maturation.
In conclusion, the comparison between the clinical features of 26
patients with 16q24.2q24.3 deletion of different sizes and 32
ANKDR11 mutated patients, show that astigmatism and thrombocy-
topenia are present exclusively in patients with the deletion involving
ZFPM1 or with breakpoints spanning up to it, as it clearly appears
from Table 1. Moreover, CDH15 haploinsufﬁciency may contribute to
a more severe neurological phenotype, with particular regard to brain
malformations, whereas ZFPM1 and ZNF778 haploinsufﬁciency may
results in an increased risk for CHDs. ZFPM1 seems also to be crucial
for correct bone marrow function as deletion for this gene seems to
result in (asymptomatic) thrombocytopenia with reduced penetrance.
All these features should be taken into account to distinguish
between KBG and 16q24 microdeletion syndromes.
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